Hyperion Therapeutics, which claims it was duped into a $570 million deal for an Israeli biotech, has reached a temporary agreement with the seller, calling off its lawyers for the moment while the two try to determine whether the drug at the heart of the acquisition has any future.
Alcobra is touting the benefits of its in-development ADHD treatment, saying the drug provided a statistically significant benefit over placebo--but only after the company removed data from four "extreme" responders from its analysis.
Troubled Teva is circling its research wagons around CNS and respiratory diseases, carving out more than $500 million in research costs over the next three years with plans to shelve or spin out 14 clinical programs as it retreats from women's health and oncology.
Early-phase CRO Accelovance has landed a former Pfizer and Otsuka exec to flesh out its efforts in oncology, part of a sweeping growth strategy that has seen the company expand across the U.S.
Reuters reports that Facebook is considering setting up patient support communities and has met with people in the medical industry to discuss its plans.
As the med tech industry addresses a growing need for devices geared toward children, a Baltimore, MA-based physician is creating 3-D printed hands developed specifically for pediatric patients.
Illumina has teamed up with AB Sciex to add proteomic data analysis capabilities to its BaseSpace platform. As a result of the collaboration, Illumina is hosting four apps for processing, analyzing and visualizing proteomics mass spectrometry data on BaseSpace.
The National Institutes of Health has forged 7 research agreements with academic and industry partners aimed at identifying new adjuvant candidates that could be used in vaccines to boost immune responses against various pathogens.
A novel treatment made by tiny Mapp Biopharmaceutical may be the key to beating back West Africa's Ebola outbreak, but despite the support of the U.S. government and some of the world's largest charities, producing enough to counter the spread will be difficult.
On Wednesday, Pfizer and Bristol-Myers Squibb got some positive data on an undo med for their market trailer, Eliquis. And that antidote could be on the way in the not-too-distant future.